Thrombotic microangiopathy in Interferon Beta treated multiple sclerosis patients: Review of literature and report of two new cases

Reza Vosoughi; James J Marriott

doi:10.1016/j.msard.2013.12.007

Thrombotic microangiopathy in Interferon Beta treated multiple sclerosis patients: Review of literature and report of two new cases

Mult Scler Relat Disord. 2014 May;3(3):321-5. doi: 10.1016/j.msard.2013.12.007. Epub 2013 Dec 28.

Authors

Reza Vosoughi¹, James J Marriott²

Affiliations

¹ Section of Neurology, University of Manitoba, Health Sciences Centre, GF-543, 820 Sherbrook Street, Winnipeg, Manitoba, Canada R3A 1R9.
² Section of Neurology, University of Manitoba, Health Sciences Centre, GF-536, 820 Sherbrook Street, Winnipeg, Manitoba, Canada R3A 1R9.

PMID: 25876469
DOI: 10.1016/j.msard.2013.12.007

Abstract

Beta interferons (IFN-β) were the first approved disease modifying therapies (DMTs) for relapsing-remitting multiple sclerosis (RRMS) and are still the most-widely prescribed medications for this disease. Despite good overall long-term safety data with prolonged use of this group of drugs, they can rarely cause serious and sometimes life threatening adverse effects. In this article we report two cases of thrombotic microangiopathy occurring during prolonged use of IFN-β and review the available literature on this topic.

Keywords: Disease modifying treatment; Interferon Beta; Malignant hypertension; Multiple sclerosis; Thrombotic microangiopathy; Thrombotic thrombocytopenic purpura.

Publication types

Review